Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 262 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder of Endocrine Ovary Clear all
Completed Not applicable Interventional Results available

Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy

NCT00746018
View directory record Official record
Conditions
Cervical Cancer, Ovarian Cancer, Uterine Cancer
Interventions
LigaSure vessel sealing system
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Pregnancy in Polycystic Ovary Syndrome II

NCT00719186
View directory record Official record
Conditions
Pregnancy, Polycystic Ovary Syndrome
Interventions
Clomiphene citrate, Letrozole
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 22, 2026, 4:52 AM EDT
Recruiting Phase 1 Interventional

Study of NTB-928 in R/R OC

NCT07690189
View directory record Official record
Conditions
Relapsed/Refractory Ovarian Carcinoma
Interventions
NTB-928
Drug
Lead sponsor
TeneoSeven, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 22, 2026, 4:52 AM EDT
Not listed Early Phase 1 Interventional

Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422746
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 22, 2026, 4:52 AM EDT
Recruiting Phase 3 Interventional

Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

NCT05819853
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Interventions
Semaglutide Injectable Product (Wegovy and/or Ozempic)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 35 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 4:52 AM EDT
Not listed Not applicable Interventional

Iyengar Yoga Therapy for Dysmenorrhea and Endometriosis

NCT03784976
View directory record Official record
Conditions
Secondary Dysmenorrhea, Dysmenorrhea, Dysmenorrhea Secondary, Polycystic Ovary Syndrome, Endometriosis, Fibroid, Menstrual Pain, Menstrual Disorder, Menstrual Discomfort
Interventions
Iyengar Yoga Therapy
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
12 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 2 Interventional

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

NCT03864068
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions
Placebo, Inositol
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer

NCT00408603
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Voreloxin Injection
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Scottsdale, Arizona • Newport Beach, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 3 Interventional

Treatment of Infertility in Women With Polycystic Ovary Syndrome

NCT00068861
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility, Pregnancy
Interventions
metformin XR, clomiphene citrate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

NCT01872078
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Interventions
AZD4901 (oral), Placebo to match AZD4901
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 22, 2026, 4:52 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?

NCT04723862
View directory record Official record
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02001623
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Tisotumab Vedotin (HuMax-TF-ADC)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Orange, California • New Haven, Connecticut • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 22, 2026, 4:52 AM EDT
Terminated Phase 1 Interventional Results available

A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

NCT05067972
View directory record Official record
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms
Interventions
PF-07260437, B7-H4 IHC
Drug · Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 22, 2026, 4:52 AM EDT
Completed No phase listed Observational

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

NCT00043472
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

NCT00381173
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Interventions
Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

NCT01196429
View directory record Official record
Conditions
Ovarian Clear Cell Cystadenocarcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Paclitaxel, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
121
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 82 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 1 Interventional

Clinical Benefit of Topoisomerase Downregulation

NCT00250094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Topotecan and VP16
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 22, 2026, 4:52 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome

NCT00930228
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Flutamide, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 22, 2026, 4:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PCOS and Brain Health

NCT07727512
View directory record Official record
Conditions
PCOS
Interventions
MRI Visit, Laboratory Visit
Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 4:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome

NCT03547453
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity, Overweight and Obesity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Not applicable Interventional

The Supporting Understanding of PCOS Education and Research (SUPER) Study

NCT05452642
View directory record Official record
Conditions
Polycystic Ovary
Interventions
DASH diet, Very low-carbohydrate diet
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 4:52 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

NCT04327934
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hypertension
Interventions
GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01853644
View directory record Official record
Conditions
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
Interventions
Tivozanib
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 110 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 22, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

NCT01889199
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 22, 2026, 4:52 AM EDT